Discover how moderate-to-vigorous physical activity can reduce exacerbations and corticosteroid use in COPD patients on dual ...

Discover the latest insights from the TOReTO study on COPD management: Dual bronchodilator therapy has been shown to reduce exacerbations, with varying efficacy between current and former smokers.

Dr. Kaelee Brockway and Dr. Shakeel Ahmed discuss the overlooked benefits of referring patients with COPD experiencing pain ...

Dupilumab in COPD was associated with decreased risk of mortality, emergency visits, exacerbations, and respiratory failure and infections.

Verona Pharma has seen its share price skyrocket in anticipation of the commercial launch of its COPD treatment.

COPD and BPD: Inhalation of Live Lactobacilli Lessens Lung Inflammation and Improves Lung Function Aug. 21, 2024 — In preclinical models, the inhalation of a mixture of living Lactobacilli ...

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3Through October more than 2,200 unique ...

Health care providers treating people with COPD also need to focus on the person's socioeconomic factors, along with ...

As AstraZeneca’s chronic obstructive pulmonary disease drug Breztri continues climbing toward blockbuster status, the Big Pharma is broadening its efforts to support people with COPD. | As AstraZeneca ...

Chronic obstructive pulmonary disease is a serious, progressive illness that hits the homeless and underinsured the hardest.

This broad utilization across all patient types is consistent with market research and supports our belief that Ohtuvayre’s bronchodilator ... advancement for COPD patients and can re-define ...

Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti ...